TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05546736

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCanWork Intervention
Description: Participants will receive RTW support from the VRC and OT.
Study: NCT05980143

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metacognitive Therapy
Description: The transdiagnostic Metacognitive model suggests that psychological difficulties arise from the activation of a thinking style called the CAS (Cognitive Attentional Syndrome). Metacognitive Therapy (MCT) aims to bring the CAS under control. The therapist helps the patient to learn new ways of relating to stressful thoughts.
Study: NCT05162196

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: 24Gy/3F

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab 240mg, ivgtt, d1, q3w.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: 200mg qd
Study: NCT05992636

Intervention type: PROCEDURE
Intervention: pneumoperitoneum insufflation (flow) rate
Description: Patiens who initiate with low insufflation flow (10 lt/min)~Patiens who initiate with high insufflation flow (40 lt/min)

Intervention type: PROCEDURE
Intervention: pneumoperitoneum insufflation (flow) rate
Description: Patiens who initiate with low insufflation flow (10 lt/min)~Patiens who initiate with high insufflation flow (40 lt/min)
Study: NCT06400797

Intervention type: OTHER
Intervention: estimation of patient outcome by health care providers
Description: On day 1 after study inclusion as well as day 4-7, the responsible health-care providers (at least one nurse, one resident and one consultant with the board certification intensive care medicine) will estimate the patient's expected functional outcome at 6 and 12 months after the start of ECMO therapy. Health-care providers responsible for the patient at that time will be surveyed (multiple questionnaires to detect specific differences within one person are not planned). For the purpose of functional outcome estimation, the modified Rankin scale (mRS) is used.
Study: NCT04775550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Oral, dosage per protocol, days 1-21 per cycle
Study: NCT06067022

Intervention type: OTHER
Intervention: observation
Description: Planned measurements and scales will be applied

Intervention type: OTHER
Intervention: observation
Description: Planned measurements and scales will be applied
Study: NCT05673499

Intervention type: DEVICE
Intervention: NIRS/EEG monitoring
Description: The study intervention will be monitoring NIRS and EEG for one hour before surgery, during surgery, and up to 8-24 hours after surgery.
Study: NCT06114134

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fenobet
Description: receiving fenugreek extract (3 capsules of 500 mg, 1 capsule half an hour before meals)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04775550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral, dosage per protocol, dose days vary per cycle. Cycle =28 days
Study: NCT06304740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007
Description: Subcutaneous injection of IMG-007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007
Description: Subcutaneous injection of IMG-007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMG-007
Description: Subcutaneous injection of IMG-007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection of Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subcutaneous Injection of Placebo
Study: NCT06338215

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Alcohol Drinking Pattern
Description: Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months.~Goals of intervention:~1. moderate consumption (7 or less drinks/wk for women, 14 or less drinks/wk for men) of red wine (a drink=150 ml).~2. always during meals~3. spread out throughout the whole week, and~4. avoidance of binge-drinking episodes. No participant will be invited to start or increase his/her alcohol intake.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Moderate Alcohol Drinking Pattern
Description: Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months.~Goals of intervention:~1. moderate consumption (7 or less drinks/wk for women, 14 or less drinks/wk for men) of red wine (a drink=150 ml).~2. always during meals~3. spread out throughout the whole week, and~4. avoidance of binge-drinking episodes. No participant will be invited to start or increase his/her alcohol intake.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Abstention
Description: Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months.~Goals of intervention:~Abstention. Message of 0 alcohol.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Abstention
Description: Remotely Intensive intervention by specialized coaches (psychologists, dietitians, and other health professionals) to promote a behavior change on alcohol consumption. Repeated quarterly small group sessions and periodical personal interviews and educational videos, during up to 4 years with 1 contact every 3 months.~Goals of intervention:~Abstention. Message of 0 alcohol.
Study: NCT06429137

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3731579
Description: BI 3731579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3731579
Description: BI 3731579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3731579
Description: BI 3731579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3731579
Description: BI 3731579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3731579
Description: BI 3731579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3731579
Description: BI 3731579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3731579
Description: BI 3731579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 3731579
Description: BI 3731579

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo to BI 3731579
Description: Matching placebo to BI 3731579
Study: NCT06420375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BRS201
Description: Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug and placebo in a 3:2 randomized order; 3 will receive active treatment for the first for four weeks followed by placebo for four weeks, while the remaining 2 will receive placebo for four weeks followed by active treatment for four weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Groups 1, 2, 3, and 4 will all contain 5 subjects each, with each subject receiving active study drug and placebo in a 3:2 randomized order; 3 will receive active treatment for the first for four weeks followed by placebo for four weeks, while the remaining 2 will receive placebo for four weeks followed by active treatment for four weeks.
Study: NCT05276011

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TG-C
Description: 2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TG-C
Description: 2 mL injection of non-transduced human chondrocytes and irradiated transduced human GP2-293 cells expressing TGF-B1.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Control
Description: 2 mL normal saline injection
Study: NCT06274710

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ODYSSEE-KH
Description: Automated digital counselling program
Study: NCT05681871

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous gluconate syrup or ferrous fumarate/folic acid tablets
Description: Oral iron supplementation dosed based on body weight
Study: NCT05201066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spartalizumab
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sabatolimab
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sabatolimab
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sabatolimab
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sabatolimab
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sabatolimab
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sabatolimab
Description: Solution for intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Solution for subcutaneous injection or intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacitidine
Description: Solution for subcutaneous injection or intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INQOVI (oral decitabine)
Description: Tablet for oral administration. HMA = azactidine or decitabine INQOVI = decitabine (oral)
Study: NCT05701722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flourish HEC Vaginal Care System
Description: BioNourish, a component of the Flourish HEC system, is a class II medical device. In addition to BioNourish, the system includes Balance intimate wash and BiopHresh homeopathic vaginal suppository with probiotics. All products are available over the counter and have been on the market for several years.
Study: NCT06126094

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Myrkl
Description: The subject of the test will be supplementation with precise probiotic for hangovers (Myrkl, De Fair) in the form of one pill of 800 mg

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: dextrin
Description: The subject of the test will be supplementation with placebo (maltodextrin) in the form of two pills (each 400 mg)
Study: NCT05576441

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: volume stable collagen matrix
Description: Volume stable collagen matrix will be placed at recipient site and suturing will be done with a 5-0 vicryl suture.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: subepithelial connective tissue graft
Description: SCTG will be harvested from donor site as per the requirement and will be placed at the recipient and suturing will be done with 5-0 vicryl suture.
Study: NCT05651438

Intervention type: OTHER
Intervention: Assessment
Description: Assessment of pain, fatigue, sleep quality, and e-sports-specific features
Study: NCT05686915

Intervention type: DIAGNOSTIC_TEST
Intervention: MARS MRI
Description: metal artifact reduction sequence (MARS) MRI to assess for fluid collections, ATLRs or other abnormalities

Intervention type: DIAGNOSTIC_TEST
Intervention: Titanium Labs
Description: Labs to look at titanium levels in blood

Intervention type: DIAGNOSTIC_TEST
Intervention: Cobalt Labs
Description: Labs to look at cobalt levels in blood

Intervention type: DIAGNOSTIC_TEST
Intervention: Chromium Labs
Description: Labs to look at chromium levels in blood
Study: NCT05912114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mannitol
Description: Mannitol, as an osmotic laxative, increases the colloid osmotic pressure in the intestinal lumen, which results in a hyperosmolar state in the intestine, thus allowing easy elimination of stools.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol electrolyte
Description: Polyethylene glycol electrolyte is an inert polymer that cannot be absorbed by the body itself. Due to its high permeability, it retains water in the intestinal tract, increasing the amount of fluid retained in the intestine and softening the stool, thus acting as a diuretic.
Study: NCT06420102

Intervention type: DIAGNOSTIC_TEST
Intervention: Biophysical and biochemical skin assessment
Description: Measurements are taken from the skin surface including transepidermal water loss, skin hydration and pH. In addition, non-invasive biofluid (sebum) is sampled from the skin to profile local inflammation. Skin surface cells were also stripped to assess corneocyte properties over the pressure ulcer and surrounding healthy skin.
Study: NCT04837521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Description: Five session psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unified Protocol
Description: Five session psychotherapy
Study: NCT05046977

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single osteotomy
Description: Single tibial osteotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double Osteotomy
Description: Double Tibial Osteotomy
Study: NCT06275659

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-100-004-A
Description: Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to strengthen inhibitory control. This intervention could help improve cognitive capabilities to help participants overcome the urge to scratch in response to an itch.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT-100-004-A
Description: Digital Neuro-activation and Modulation (DiNaMo) component uses implicit training to strengthen inhibitory control. This intervention could help improve cognitive capabilities to help participants overcome the urge to scratch in response to an itch.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CT-100-004-B
Description: The CT-100-D-004-B Processing speed training component uses implicit training targeting processing speed. This intervention could help improve cognitive capabilities to help participants overcome the urge to scratch in response to an itch.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CT-100-004-B
Description: The CT-100-D-004-B Processing speed training component uses implicit training targeting processing speed. This intervention could help improve cognitive capabilities to help participants overcome the urge to scratch in response to an itch.
Study: NCT05900219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HL-085+Vemurafenib
Description: The treatment regimen was HL-085 9mg BID+ Vemurafenib 720mg BID oral administration for 21 days per cycle. The primary efficacy endpoint in this study was the ORR assessed by the Independent Review Committee (IRC) according to the RECIST 1.1
Study: NCT05306236

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LLL therapy , postural correction ex
Description: study group: will receive low level laser therapy 2 sessions per week for 6 weeks in addition to posture correction exercises.~control group: will be treated by posture correction ex only.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: LLL therapy , postural correction ex
Description: study group: will receive low level laser therapy 2 sessions per week for 6 weeks in addition to posture correction exercises.~control group: will be treated by posture correction ex only.
Study: NCT05570370

Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study

Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study
Study: NCT05957224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shake 1 then Shake 2
Description: Oral administration of Caribbean low-calorie meal-replacement shake then commercial low-calorie meal-replacement shake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shake 2 then Shake 1
Description: Oral administration of commercial low-calorie meal-replacement shake then Caribbean low-calorie meal-replacement shake
Study: NCT05955963

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal auscultation
Description: spectral analysis of Bowel sounds
Study: NCT05495919

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No intervention was perfomed to reduce anxiety in control group

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: video interaction
Description: Before the training, educational materials were given to the students, and they were discussed with the students in the lesson.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flipped training
Description: Before the training, the students took videos and during the lesson, the videos were evaluated and feedback was given.
Study: NCT05858801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRIMUS
Description: PRIMUS system
Study: NCT05135923

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Randomized, controlled trial (RCT) with parallel arms and double blinded
Description: Experiment group receive optimized gluten free products (high in fiber and whole grain) compared to comparable benchmark gluten free products (control group).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Randomized, controlled trial (RCT) with parallel arms and double blinded
Description: Experiment group receive optimized gluten free products (high in fiber and whole grain) compared to comparable benchmark gluten free products (control group).
Study: NCT05475496

Intervention type: OTHER
Intervention: Measurements of quality of life and burnout
Description: WHOQOL-Bref questionnaire to assess the health related quality of life of the elderly cardiac patients. WHOQOL-Bref assesses Physical health (7 items), Psychological health (6 items), Social relationships (3 items) and the environment ( 8 items ), in addition to two items asking about overall perception of life and general health. Items are rated on a 5 point ordinal scale, domain scores are scaled in a positive direction (i.e. higher scores denote higher quality of life).~Maslach Burnout Inventory questionnaire to measure burnout among caregivers, it includes 3 components: emotional exhaustion (9 items), depersonalization(5items) and personal accomplishment(8 items).
Study: NCT04927338

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BacoMind® (Bacopa monnieri standardized extract)
Description: BacoMind® (Bacopa monnieri standardized extract) 300 mg daily capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily placebo capsule identical in size, color, and shape to that of the Bacopa capsules.
Study: NCT04868253

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMB-01
Description: EMB-001 is a proprietary combination of metyrapone (a cortisol synthesis inhibitor) and oxazepam (a short to medium acting benzodiazepine).
Study: NCT05884983

Intervention type: PROCEDURE
Intervention: participants will undergo dual-energy CT and endoscopy
Description: Diagnostic Test: P85-Ab,EBNA1-IgA,and VCA-IgA. Detect P85-Ab, EBNA1-IgA, VCA-IgA for all participants and select serological high-risk participants DiagnosticTest: dual-energy CT, endoscopy and biopsy. serological high-risk participants will refer to dual-energy CT, endoscopy and biospy
Study: NCT05816577

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: EcN Colibactin knockout
Description: E coli Nissle strain with ClbP-gene removed and therefore not producing colibactin

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: E Coli Nissle
Description: E Coli wildtype strain
Study: NCT05727033

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Participatory teaching group
Description: The intervention will be called FEDE-ITS® methodology. This methodology is self-designed and self-developed and draws on previous work in equivalent populations. It is based on teaching in a participatory way knowledge and healthy attitudes related to the five most prevalent STIs in the province of Barcelona and Lleida, the methods to avoid contagion, and the health resources that can be consulted in case of infection, contact with an infected person or concerns. In addition, a gender perspective is incorporated to contribute to freer and more egalitarian relationships and reduce the likelihood of violence against women which develops in adolescence.~The cross-cutting themes of the training are: health, pleasure, self-esteem, knowledge-based freedom of choice, equality between people and respect for sexual freedom. Therefore, the ultimate goal is to prevent abusive power relations and macho violence.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham control group
Description: The Health and School program was implemented to promote health in schools, and for this reason the program's nurse attends annually to address problems related to sexual affective health within the curricular itinerary of each school, but not specifically on sexually transmitted infections or gender perspective.
Study: NCT06291532

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation with VRRS
Description: The patients underwent an experimental intervention lasting two months (9 sessions lasting about 40 minutes) integrated into the regular activity of a semi-residential center for autistic adolescents and young adults.~The proposed exercises were 2D and the patient interacted with the scenarios through the touch screen. For all participants, the tasks were the same, but difficulty and duration varied according to the needs and goals to be achieved.